Form 4: Phathom CEO Exercises Options, Sells Shares for Tax

Phathom Pharmaceuticals CEO Steven L. Basta exercised performance stock units and sold a portion of the resulting common stock to cover tax obligations.

Summary

• Steven L. Basta, President and CEO of Phathom Pharmaceuticals, Inc., exercised 90,000 performance stock units (PSUs) into common stock on November 28, 2025.
• These PSUs vested due to the achievement of a stock price hurdle, as part of a larger grant of 360,000 PSUs on April 3, 2025.
• Concurrently, Basta disposed of 48,375 shares of common stock at a price of $15.62 per share to satisfy tax withholding obligations related to the vesting.
• Following these transactions, Basta beneficially owns 83,250 shares of common stock directly and 180,000 derivative performance stock units.

Sentiment

Score: 7

Explanation: The vesting of performance stock units indicates the company met stock price performance targets, which is generally positive. The subsequent sale of shares is a standard practice for tax withholding and not indicative of negative sentiment regarding the company's future.

Positives

• The vesting of 90,000 performance stock units indicates the achievement of a pre-defined stock price hurdle, reflecting positive stock performance for Phathom Pharmaceuticals, Inc.

Negatives

• A disposition of 48,375 shares of common stock occurred, reducing direct beneficial ownership, although this was for tax withholding purposes.

Future Outlook

The remaining performance stock units granted to Steven L. Basta will vest based on the achievement of future stock price hurdles over a period of four years following the grant date, subject to his continued service.

Management Comments

• The disposition of 48,375 shares of common stock was made to satisfy the Issuer's tax withholding obligation related to the vesting of performance stock units.

Industry Context

This Form 4 filing details a routine insider transaction, common for executives whose compensation includes equity awards. The exercise of performance stock units and subsequent sale for tax purposes is a standard event in the biotechnology and pharmaceutical industry, where executive compensation is often heavily weighted towards stock-based incentives tied to company performance.

Related Party Transactions

• Steven L. Basta, President and CEO, exercised performance stock units granted by Phathom Pharmaceuticals, Inc.
• Shares were disposed of to the Issuer to satisfy tax withholding obligations related to the vesting of performance stock units.

Stakeholder Impact

• Shareholders: The vesting of performance stock units suggests positive stock performance, which generally benefits shareholders. The sale for tax purposes is a minor, expected dilution.
• Management: Steven L. Basta's compensation structure, tied to stock performance through PSUs, aligns his interests with those of shareholders.

Next Steps

• Remaining performance stock units will vest based on the achievement of future stock price hurdles over a four-year period, subject to continued service.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the exercise of vested performance stock units and a subsequent sale of shares to cover tax liabilities. While the vesting indicates the achievement of stock price hurdles, which is a positive reflection on the company's performance, the transaction itself does not provide new fundamental information to warrant a change in investment thesis. It is a standard compensation event for an executive and does not suggest a significant shift in the company's outlook or valuation.

Keywords

Phathom Pharmaceuticals, PHAT, Steven L. Basta, Form 4, insider transaction, stock options, performance stock units, CEO, stock sale, tax withholding